From: Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study
 | Baseline | Week 24 | Week 48 | |||
---|---|---|---|---|---|---|
 | n | Mean (SD), ng/mL | n | Mean (SD), ng/mL | n | Mean (SD), ng/mL |
Total population | Â | Â | Â | Â | Â | Â |
Migraine (N = 623) | 622 | 2.59 (0.69) | 587 | 2.60 (0.67) | 233 | 2.66 (0.65) |
Responders* (n = 282) | 282 | 2.54 (0.62) | 276 | 2.56 (0.64) | 97 | 2.52 (0.52)‡ |
Non-responders* (n = 259) | 258 | 2.62 (0.72) | 246 | 2.62 (0.65) | 118 | 2.75 (0.69)†,‡ |
Migraine with aura subgroup | Â | Â | Â | Â | Â | Â |
Migraine (n = 183) | 182 | 2.70 (0.76)†| 173 | 2.76 (0.73)†| 67 | 2.85 (0.79)†|
Responders* (n = 81) | 81 | 2.62 (0.72) | 79 | 2.65 (0.61) | 28 | 2.57 (0.63) |
Non-responders* (n = 77) | 76 | 2.80 (0.83)†| 72 | 2.76 (0.78)†| 36 | 3.05 (0.82)†|
Healthy controls | Â | Â | Â | Â | Â | Â |
Healthy controls (n = 154) | 154 | 2.44 (0.56)†| - | - | - | - |